Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK2D | Q13557 | 6/20 | 0.78 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.67 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.67 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.67 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.65 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.65 |
| ▸ | GSK3B | P49841 | 1/20 | 0.65 |
| ▸ | IKBKB | O14920 | 2/20 | 0.64 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.63 |
| ▸ | AURKA | O14965 | 3/20 | 0.60 |
| ▸ | PLK1 | P53350 | 1/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | JAK3 | P52333 | 1/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.56 |
| ▸ | KMO | O15229 | 1/20 | 0.56 |
| ▸ | CLK1 | P49759 | 1/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.55 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.55 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.55 |
| ▸ | CHUK | O15111 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13049909 | 0.88 | PIK3CA (0.66) | CAMK2DPIK3CGPIK3CAPIK3CBMAPK8 | |
| SCHEMBL4070306 | 0.88 | MAPK8 (0.77) | CAMK2DPIK3CGPIK3CAPIK3CBMAPK8 | |
| SCHEMBL14021126 | 0.88 | CAMK2D (0.61) | CAMK2DPIK3CGPIK3CAPIK3CBMAPK8 | |
| SCHEMBL14021028 | 0.87 | PIK3CA (0.64) | CAMK2DPIK3CGPIK3CAPIK3CBMAPK8 | |
| SCHEMBL4800404 | 0.87 | MAPK8 (0.83) | CAMK2DPIK3CGMAPK8CAMKK2GSK3B | |
| SCHEMBL7464657 | 0.86 | CAMK2D (0.90) | CAMK2DPIK3CGMAPK8CAMKK2GSK3B | |
| SCHEMBL4072590 | 0.86 | PIK3CA (0.70) | CAMK2DPIK3CGPIK3CAPIK3CBMAPK8 | |
| SCHEMBL14021024 | 0.86 | PIK3CA (0.63) | CAMK2DPIK3CGPIK3CAPIK3CBMAPK8 | |
| SCHEMBL14021038 | 0.86 | CAMK2D (0.71) | CAMK2DPIK3CGPIK3CAPIK3CBMAPK8 | |
| SCHEMBL4066872 | 0.85 | PIK3CA (0.62) | CAMK2DPIK3CGPIK3CAPIK3CBMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349841-B1 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARM LLC (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-1349841-B1 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARM LLC (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-1349840-B1 | ANILINOPYRIMIDINE DERIVATIVES AS JNK PATHWAY INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARM LLC (US) | 2009-03-11 | — | — | EP | disclosed |
| EP-1349840-B1 | ANILINOPYRIMIDINE DERIVATIVES AS JNK PATHWAY INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARM LLC (US) | 2009-03-11 | — | — | EP | disclosed |
| US-7442699-B2 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442699-B2 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442699-B2 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-10-28 | — | — | US | disclosed |
| US-7429599-B2 | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429599-B2 | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429599-B2 | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-09-30 | — | — | US | disclosed |
| EP-1608375-A1 | METHODS FOR TREATING OR PREVENTING AN INFLAMMATORY OR METABOLIC CONDITION BY INHIBITING JNK | Signal Pharmaceuticals LLC (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004084901-A1 | METHODS FOR TREATING OR PREVENTING AN INFLAMMATORY OR METABOLIC CONDITION BY INHIBITING JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004084901-A1 | METHODS FOR TREATING OR PREVENTING AN INFLAMMATORY OR METABOLIC CONDITION BY INHIBITING JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040106634-A1 | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-06-03 | — | — | US | disclosed |
| US-20030220330-A1 | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2003-11-27 | — | — | US | disclosed |
| US-20030203926-A1 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2003-10-30 | — | — | US | disclosed |
| EP-1349841-A2 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-10-08 | — | — | EP | disclosed |
| EP-1349840-A2 | ANILINOPYRIMIDINE DERIVATIVES AS JNK PATHWAY INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002046171-A2 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002046170-A2 | ANILINOPYRIMIDINE DERIVATIVES AS JNK PATHWAY INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106634-A1 | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK | MAPK6, MAPKAPK2, DUSP6 | CAMK2D 351/4885PIK3CG 3039/4885PIK3CA 2501/4885 |
| US-20030203926-A1 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | NFKBIA, IKBKB, IKBKE | CAMK2D 352/4885PIK3CG 34/4885PIK3CA 21/4885 |
| US-20030220330-A1 | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto | MAPK6, MAP3K6, MAPK1 | CAMK2D 333/4885PIK3CG 249/4885PIK3CA 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.